Investigators hope that an experimental test could detect the novel coronavirus at a much lower cost than current tests; the FDA has extended the action date for a chimeric antigen receptor (CAR) T-cell therapy application from Bristol Myers Squibb (BMS); engineering teams devise inexpensive ventilators for emergency use.
A team of researchers has produced an experimental prototype of a test to diagnose the novel coronavirus that causes coronavirus disease 2019 (COVID-19) using CRISPR gene-editing technology, according to The New York Times. Other groups have published results of experiments with CRISPR-based coronavirus tests, but the new method uses a simpler process that reduces the cost to about $6 per test. However, experts cautioned that the tests are merely a proof of concept and the findings have not undergone peer review, making it unclear how the test would fare in real-world conditions.
After Bristol Myers Squibb (BMS) submitted additional information to supplement its biologics license application for lisocabtagene maraleucel (liso-cel), the FDA has extended the Prescription Drug User Fee Act date by 3 months to November 16, 2020. The extension was announced in a release from BMS in which the company noted that it remains committed to bringing the therapy to patients. Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed/refractory large B-cell lymphoma in adults who have tried at least 2 prior therapies.
Engineering departments at universities nationwide are teaming up to design low-cost emergency ventilators after the COVID-19 pandemic has uncovered shortages in the supply chain, Forbes reports. For instance, a team led by C. Nataraj, PhD, an engineering professor at Villanova University, has produced a prototype of a ventilator that could be manufactured by local businesses for less than $1000. Although manufacturing will not be ramped up in time to help with the first wave of COVID-19 in the United States, the devices emerging from these efforts could help hospitals if there is a second wave or could be sent to low-income countries with an already low supplies of ventilators.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
FDA Approves Ravulizumab-cwvz for Rare Autoimmune Disease
March 28th 2024Ravulizumab-cwvz (Ultomiris) received a label expansion by the FDA for the treatment of adult neuromyelitis optica spectrum disorder in patients with anti–aquaporin-4 antibodies after trials results showed it could prevent relapses.
Read More
Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles
March 28th 2024In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
FDA Approves Ravulizumab-cwvz for Rare Autoimmune Disease
March 28th 2024Ravulizumab-cwvz (Ultomiris) received a label expansion by the FDA for the treatment of adult neuromyelitis optica spectrum disorder in patients with anti–aquaporin-4 antibodies after trials results showed it could prevent relapses.
Read More
Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles
March 28th 2024In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.
Read More
2 Commerce Drive
Cranbury, NJ 08512